Roelof Botha, the head of Sequoia Capital, is coming to TechCrunch Disrupt 2025
We're thrilled to announce that Roelof Botha, the managing partner of Sequoia Capital and one of the most influential figures in the venture capital world, will join us live onstage at TechCrunch Disrupt 2025 at Moscone West in San Francisco, which will take place from October 27 to 29.
As part of our ongoing mission to bring smart, future-focused conversations to the venture and startup community, having Botha — a leader who's helped shape some of the most iconic tech companies of the last two decades — join us feels particularly critical this year, and for good reason.
First, the venture industry is fast evolving, with the most established venture firms beginning to operate like far broader investment firms, a once-secondary secondary market taking center stage, and the field of venture participants actively shrinking as exits become harder to achieve.
The dynamics between VCs and founders are also shifting in this new AI-powered era. Startups are growing faster than ever — and in some cases, requiring unprecedented amounts of capital to compete and thrive. We want to know from Botha how Sequoia is thinking about everything in 2025, from deal flow to due diligence to the expectations around building and scaling companies, especially given the powerful concentration of several of the biggest players.
Lastly, this year is the 20th anniversary of TechCrunch, and Sequoia Capital has been at the center of the startup industry, about which we are so passionate. What's more, Roelof has been a central figure in our programming over the years; we couldn't imagine a Disrupt that celebrates this milestone anniversary without him.
Stay tuned to the for more speaker announcements, and if you care about where venture is heading, this is one conversation you won't want to miss.
with Early Bird pricing. Don't miss Botha — one of the most influential leaders in VC — and your chance to lock in these savings. Snag your ticket here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
12 hours ago
- Bloomberg
Neuralink Raises $650 Million in Late-Stage Funding Round
Neuralink Corp., Elon Musk's brain chip company, raised $650 million in a Series E funding round. At least 11 investment firms, including ARK Investment Management, Founders Fund and Sequoia Capital, participated in the round, according to a statement released Monday. Since the previous funding round in August 2023, the company said it has enrolled five patients with severe paralysis and announced a clinical trial in Abu Dhabi on May 14.
TechCrunch
15 hours ago
- TechCrunch
Elon Musk's Neuralink closes a $650M Series E
In Brief Elon Musk's brain computer interface startup Neuralink closed a $650 million funding round, the company announced in a blog post on Monday. The Series E fundraise included investors such as ARK Invest, Founders Fund, Sequoia Capital, and Thrive Capital, among others. Neuralink last raised a $280 million Series D funding round in 2023, with an additional $43 million tranche added months later. Since then, Neuralink's brain chip technology has made some significant leaps. The company says it has now conducted more human clinical trials, implanting its brain chips in five individuals with severe paralysis. In May, Neuralink received breakthrough device designation from the U.S. Food and Drug Administration, a program intended to speed up development, assessment, and review processes for experimental technologies. Semafor reported last week that this latest deal values Neuralink at around $9 billion pre-money.
Business Insider
a day ago
- Business Insider
BeOne Medicines to present new data from Phase 3 SEQUOIA trial of BRUKINSA
BeOne Medicines (ONC) will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in line with recent fixed-duration studies in fitter, healthier patient populations. Additionally, 11 patients in Arm D were able to discontinue treatment early due to meeting uMRD-guided stopping criteria, and 9 patients remain in ongoing clinical remission with sustained uMRD, allowing them to remain treatment-free. In patients without del(17p) and TP53 mutations, 43% achieved uMRD by cycle 16 and 60% by cycle 28. These data were published today in the Journal of Clinical Oncology. Confident Investing Starts Here:
